2023年12月期 第３四半期決算短信〔ＩＦＲＳ〕（連結）

This document is the consolidated financial results for the third quarter of the fiscal year ending December 2023 for GNI Group, Inc. Released on November 14, 2023, it reports a 61.0% increase in revenue to 20,547 million yen, a 355.3% increase in operating profit to 6,802 million yen, and a 421.3% increase in profit before tax to 6,376 million yen, with quarterly profit rising to 4,804 million yen compared to the same period last year. Notably, sales of the main product, Isuliyu, from the subsidiary Beijing Continent Pharmaceutical have been strong, and the clinical trial for F351 is progressing. Overall, the company continues to grow despite a challenging economic environment.